JP2004500019A - 定方向進化におけるエキソヌクレアーゼ仲介核酸再集合 - Google Patents

定方向進化におけるエキソヌクレアーゼ仲介核酸再集合 Download PDF

Info

Publication number: JP2004500019A
Authority: JP; Japan
Prior art keywords: polynucleotide; nucleic acid; exonuclease; polynucleotides; sequence
Prior art date: 1999-03-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2000608795A

Other languages

English (en)

Japanese (ja)

Inventor

ショート、ジェイ、エム．

ヤワキシュヴィリ，ソーネ，デイヴィッド

フレイ，ゲルハルド，ジョアン

Original Assignee

ディベルサ　コーポレーション

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-26

Filing date

2000-03-27

Publication date

2004-01-08

1999-03-26 Priority claimed from US09/276,860 external-priority patent/US6352842B1/en

1999-06-14 Priority claimed from US09/332,835 external-priority patent/US6537776B1/en

2000-03-27 Application filed by ディベルサ　コーポレーション filed Critical ディベルサ　コーポレーション

2004-01-08 Publication of JP2004500019A publication Critical patent/JP2004500019A/ja

Status Pending legal-status Critical Current

Links

150000007523 nucleic acids Chemical class 0.000 title claims abstract description 285
102000039446 nucleic acids Human genes 0.000 title claims abstract description 233
108020004707 nucleic acids Proteins 0.000 title claims abstract description 233
108060002716 Exonuclease Proteins 0.000 title claims abstract description 90
102000013165 exonuclease Human genes 0.000 title claims abstract description 90
230000001404 mediated effect Effects 0.000 title claims abstract description 40
102000040430 polynucleotide Human genes 0.000 claims abstract description 581
108091033319 polynucleotide Proteins 0.000 claims abstract description 580
239000002157 polynucleotide Substances 0.000 claims abstract description 579
238000000034 method Methods 0.000 claims abstract description 343
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 221
108090000623 proteins and genes Proteins 0.000 claims abstract description 190
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 147
229920001184 polypeptide Polymers 0.000 claims abstract description 125
238000002703 mutagenesis Methods 0.000 claims abstract description 80
231100000350 mutagenesis Toxicity 0.000 claims abstract description 80
230000014509 gene expression Effects 0.000 claims abstract description 61
239000002773 nucleotide Substances 0.000 claims description 110
125000003729 nucleotide group Chemical group 0.000 claims description 108
230000008569 process Effects 0.000 claims description 79
241000894007 species Species 0.000 claims description 76
230000027455 binding Effects 0.000 claims description 74
238000012216 screening Methods 0.000 claims description 48
238000000338 in vitro Methods 0.000 claims description 43
239000012634 fragment Substances 0.000 claims description 39
230000000670 limiting effect Effects 0.000 claims description 36
238000004519 manufacturing process Methods 0.000 claims description 31
238000011282 treatment Methods 0.000 claims description 31
238000009396 hybridization Methods 0.000 claims description 23
241000588724 Escherichia coli Species 0.000 claims description 22
230000037361 pathway Effects 0.000 claims description 22
239000013604 expression vector Substances 0.000 claims description 19
230000002255 enzymatic effect Effects 0.000 claims description 16
238000000137 annealing Methods 0.000 claims description 14
230000000295 complement effect Effects 0.000 claims description 14
108010052305 exodeoxyribonuclease III Proteins 0.000 claims description 14
102000003960 Ligases Human genes 0.000 claims description 12
108090000364 Ligases Proteins 0.000 claims description 12
101710163270 Nuclease Proteins 0.000 claims description 12
108010068698 spleen exonuclease Proteins 0.000 claims description 12
101100226347 Escherichia phage lambda exo gene Proteins 0.000 claims description 11
108010010677 Phosphodiesterase I Proteins 0.000 claims description 11
230000003578 releasing effect Effects 0.000 claims description 11
239000002253 acid Substances 0.000 claims description 9
238000001400 expression cloning Methods 0.000 claims description 8
238000004925 denaturation Methods 0.000 claims description 7
230000036425 denaturation Effects 0.000 claims description 7
108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 6
102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 6
108010086093 Mung Bean Nuclease Proteins 0.000 claims description 5
238000000926 separation method Methods 0.000 claims description 5
102000012410 DNA Ligases Human genes 0.000 claims description 4
108010061982 DNA Ligases Proteins 0.000 claims description 4
230000009977 dual effect Effects 0.000 claims description 4
125000005842 heteroatom Chemical group 0.000 claims description 3
230000001737 promoting effect Effects 0.000 claims description 3
230000037452 priming Effects 0.000 claims description 2
102000004190 Enzymes Human genes 0.000 abstract description 110
108090000790 Enzymes Proteins 0.000 abstract description 110
239000013598 vector Substances 0.000 abstract description 107
239000000427 antigen Substances 0.000 abstract description 27
108091007433 antigens Proteins 0.000 abstract description 26
102000036639 antigens Human genes 0.000 abstract description 26
230000001965 increasing effect Effects 0.000 abstract description 18
230000004071 biological effect Effects 0.000 abstract description 13
230000008901 benefit Effects 0.000 abstract description 7
230000002068 genetic effect Effects 0.000 abstract description 6
230000003834 intracellular effect Effects 0.000 abstract description 5
229960005486 vaccine Drugs 0.000 abstract description 4
150000003384 small molecules Chemical class 0.000 abstract description 3
239000003242 anti bacterial agent Substances 0.000 abstract description 2
229940088710 antibiotic agent Drugs 0.000 abstract description 2
238000002651 drug therapy Methods 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000000704 physical effect Effects 0.000 abstract 1
230000009261 transgenic effect Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 121
229940088598 enzyme Drugs 0.000 description 108
235000001014 amino acid Nutrition 0.000 description 100
108020004414 DNA Proteins 0.000 description 79
102000004169 proteins and genes Human genes 0.000 description 79
230000006798 recombination Effects 0.000 description 79
238000005215 recombination Methods 0.000 description 78
235000018102 proteins Nutrition 0.000 description 75
150000001413 amino acids Chemical group 0.000 description 74
229940024606 amino acid Drugs 0.000 description 72
230000035772 mutation Effects 0.000 description 71
229910052757 nitrogen Inorganic materials 0.000 description 65
230000000694 effects Effects 0.000 description 64
108091028043 Nucleic acid sequence Proteins 0.000 description 54
101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 43
102100024952 Protein CBFA2T1 Human genes 0.000 description 43
239000000047 product Substances 0.000 description 41
125000003275 alpha amino acid group Chemical group 0.000 description 38
108020004705 Codon Proteins 0.000 description 34
108091034117 Oligonucleotide Proteins 0.000 description 34
239000000203 mixture Substances 0.000 description 33
102000005962 receptors Human genes 0.000 description 33
108020003175 receptors Proteins 0.000 description 33
108010047041 Complementarity Determining Regions Proteins 0.000 description 31
238000006467 substitution reaction Methods 0.000 description 31
238000006243 chemical reaction Methods 0.000 description 29
238000003776 cleavage reaction Methods 0.000 description 28
230000007017 scission Effects 0.000 description 28
230000015572 biosynthetic process Effects 0.000 description 26
108091032973 (ribonucleotides)n+m Proteins 0.000 description 25
229920002521 macromolecule Polymers 0.000 description 24
239000013612 plasmid Substances 0.000 description 24
241001515965 unidentified phage Species 0.000 description 24
238000003786 synthesis reaction Methods 0.000 description 22
238000001727 in vivo Methods 0.000 description 21
239000013615 primer Substances 0.000 description 21
230000001105 regulatory effect Effects 0.000 description 21
238000013518 transcription Methods 0.000 description 21
230000035897 transcription Effects 0.000 description 21
241000282414 Homo sapiens Species 0.000 description 20
230000003321 amplification Effects 0.000 description 20
238000003199 nucleic acid amplification method Methods 0.000 description 20
239000002243 precursor Substances 0.000 description 20
238000010367 cloning Methods 0.000 description 19
108020001507 fusion proteins Proteins 0.000 description 19
102000037865 fusion proteins Human genes 0.000 description 19
239000003550 marker Substances 0.000 description 19
108700005078 Synthetic Genes Proteins 0.000 description 18
238000013459 approach Methods 0.000 description 18
-1 hosts Substances 0.000 description 18
239000003446 ligand Substances 0.000 description 18
238000012217 deletion Methods 0.000 description 17
230000037430 deletion Effects 0.000 description 17
230000006870 function Effects 0.000 description 16
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 15
239000013599 cloning vector Substances 0.000 description 15
238000013461 design Methods 0.000 description 15
239000000523 sample Substances 0.000 description 15
108060003951 Immunoglobulin Proteins 0.000 description 14
239000003623 enhancer Substances 0.000 description 14
108091008053 gene clusters Proteins 0.000 description 14
102000018358 immunoglobulin Human genes 0.000 description 14
108091008146 restriction endonucleases Proteins 0.000 description 14
238000007792 addition Methods 0.000 description 13
230000007062 hydrolysis Effects 0.000 description 13
238000006460 hydrolysis reaction Methods 0.000 description 13
230000010076 replication Effects 0.000 description 13
241000894006 Bacteria Species 0.000 description 12
230000007613 environmental effect Effects 0.000 description 12
239000000758 substrate Substances 0.000 description 12
108091026890 Coding region Proteins 0.000 description 11
102000053602 DNA Human genes 0.000 description 11
244000005700 microbiome Species 0.000 description 11
230000003252 repetitive effect Effects 0.000 description 11
239000000126 substance Substances 0.000 description 11
241000196324 Embryophyta Species 0.000 description 10
230000009471 action Effects 0.000 description 10
238000003780 insertion Methods 0.000 description 10
230000037431 insertion Effects 0.000 description 10
230000007935 neutral effect Effects 0.000 description 10
239000002245 particle Substances 0.000 description 10
230000001568 sexual effect Effects 0.000 description 10
102000004157 Hydrolases Human genes 0.000 description 9
108090000604 Hydrolases Proteins 0.000 description 9
108091092195 Intron Proteins 0.000 description 9
230000029087 digestion Effects 0.000 description 9
230000009897 systematic effect Effects 0.000 description 9
108010011619 6-Phytase Proteins 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
230000001580 bacterial effect Effects 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
230000036961 partial effect Effects 0.000 description 8
229940085127 phytase Drugs 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
238000002741 site-directed mutagenesis Methods 0.000 description 8
206010059866 Drug resistance Diseases 0.000 description 7
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 7
238000012408 PCR amplification Methods 0.000 description 7
241000700605 Viruses Species 0.000 description 7
239000011324 bead Substances 0.000 description 7
230000008859 change Effects 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
238000002156 mixing Methods 0.000 description 7
210000004940 nucleus Anatomy 0.000 description 7
210000002729 polyribosome Anatomy 0.000 description 7
230000008707 rearrangement Effects 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
238000012546 transfer Methods 0.000 description 7
108010067902 Peptide Library Proteins 0.000 description 6
108010030975 Polyketide Synthases Proteins 0.000 description 6
108020004511 Recombinant DNA Proteins 0.000 description 6
238000003314 affinity selection Methods 0.000 description 6
125000003118 aryl group Chemical group 0.000 description 6
238000012219 cassette mutagenesis Methods 0.000 description 6
230000021615 conjugation Effects 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
210000003527 eukaryotic cell Anatomy 0.000 description 6
238000002744 homologous recombination Methods 0.000 description 6
230000006801 homologous recombination Effects 0.000 description 6
210000004408 hybridoma Anatomy 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
238000012545 processing Methods 0.000 description 6
238000011084 recovery Methods 0.000 description 6
238000012163 sequencing technique Methods 0.000 description 6
238000001890 transfection Methods 0.000 description 6
238000005406 washing Methods 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
229910019142 PO4 Inorganic materials 0.000 description 5
240000004808 Saccharomyces cerevisiae Species 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 5
235000014633 carbohydrates Nutrition 0.000 description 5
150000001768 cations Chemical class 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
239000003814 drug Substances 0.000 description 5
230000005847 immunogenicity Effects 0.000 description 5
230000003993 interaction Effects 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
229920001542 oligosaccharide Polymers 0.000 description 5
150000002482 oligosaccharides Chemical class 0.000 description 5
230000003647 oxidation Effects 0.000 description 5
238000007254 oxidation reaction Methods 0.000 description 5
239000010452 phosphate Substances 0.000 description 5
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 5
229930001119 polyketide Natural products 0.000 description 5
125000000830 polyketide group Chemical group 0.000 description 5
238000011160 research Methods 0.000 description 5
230000009466 transformation Effects 0.000 description 5
238000013519 translation Methods 0.000 description 5
239000004475 Arginine Substances 0.000 description 4
101710132601 Capsid protein Proteins 0.000 description 4
108090000994 Catalytic RNA Proteins 0.000 description 4
102000053642 Catalytic RNA Human genes 0.000 description 4
101710094648 Coat protein Proteins 0.000 description 4
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
241000701959 Escherichia virus Lambda Species 0.000 description 4
108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
102000003886 Glycoproteins Human genes 0.000 description 4
108090000288 Glycoproteins Proteins 0.000 description 4
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 4
101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 4
101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 4
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
101710125418 Major capsid protein Proteins 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
101710141454 Nucleoprotein Proteins 0.000 description 4
101710083689 Probable capsid protein Proteins 0.000 description 4
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
101710183280 Topoisomerase Proteins 0.000 description 4
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
235000008206 alpha-amino acids Nutrition 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
230000003197 catalytic effect Effects 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
238000010276 construction Methods 0.000 description 4
238000004520 electroporation Methods 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
238000001415 gene therapy Methods 0.000 description 4
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
102000054751 human RUNX1T1 Human genes 0.000 description 4
238000011534 incubation Methods 0.000 description 4
229960000310 isoleucine Drugs 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
231100000219 mutagenic Toxicity 0.000 description 4
230000003505 mutagenic effect Effects 0.000 description 4
230000004962 physiological condition Effects 0.000 description 4
230000008488 polyadenylation Effects 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
238000013138 pruning Methods 0.000 description 4
108091092562 ribozyme Proteins 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
230000009870 specific binding Effects 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
241000701161 unidentified adenovirus Species 0.000 description 4
241001430294 unidentified retrovirus Species 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
239000004474 valine Substances 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
108090000565 Capsid Proteins Proteins 0.000 description 3
241000701489 Cauliflower mosaic virus Species 0.000 description 3
102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 3
102100023321 Ceruloplasmin Human genes 0.000 description 3
108091028732 Concatemer Proteins 0.000 description 3
102000003915 DNA Topoisomerases Human genes 0.000 description 3
108090000323 DNA Topoisomerases Proteins 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
108090000371 Esterases Proteins 0.000 description 3
241000206602 Eukaryota Species 0.000 description 3
101710185850 Exodeoxyribonuclease Proteins 0.000 description 3
241000724791 Filamentous phage Species 0.000 description 3
108700039691 Genetic Promoter Regions Proteins 0.000 description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
108090001060 Lipase Proteins 0.000 description 3
102000004882 Lipase Human genes 0.000 description 3
239000004367 Lipase Substances 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
108091000080 Phosphotransferase Proteins 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
239000004365 Protease Substances 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
239000004098 Tetracycline Substances 0.000 description 3
108020004440 Thymidine kinase Proteins 0.000 description 3
108091023045 Untranslated Region Proteins 0.000 description 3
101150117115 V gene Proteins 0.000 description 3
108010067390 Viral Proteins Proteins 0.000 description 3
150000001371 alpha-amino acids Chemical class 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
210000004436 artificial bacterial chromosome Anatomy 0.000 description 3
235000009582 asparagine Nutrition 0.000 description 3
229960001230 asparagine Drugs 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000002759 chromosomal effect Effects 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
239000013601 cosmid vector Substances 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
229940079593 drug Drugs 0.000 description 3
150000002118 epoxides Chemical class 0.000 description 3
238000013401 experimental design Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000033444 hydroxylation Effects 0.000 description 3
238000005805 hydroxylation reaction Methods 0.000 description 3
229940072221 immunoglobulins Drugs 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
101150109249 lacI gene Proteins 0.000 description 3
235000019421 lipase Nutrition 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
230000011987 methylation Effects 0.000 description 3
238000007069 methylation reaction Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
102000020233 phosphotransferase Human genes 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
210000001236 prokaryotic cell Anatomy 0.000 description 3
230000006337 proteolytic cleavage Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000002708 random mutagenesis Methods 0.000 description 3
230000037432 silent mutation Effects 0.000 description 3
229910052717 sulfur Inorganic materials 0.000 description 3
239000011593 sulfur Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
229960002180 tetracycline Drugs 0.000 description 3
229930101283 tetracycline Natural products 0.000 description 3
235000019364 tetracycline Nutrition 0.000 description 3
150000003522 tetracyclines Chemical class 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000001131 transforming effect Effects 0.000 description 3
230000017105 transposition Effects 0.000 description 3
210000005253 yeast cell Anatomy 0.000 description 3
HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 2
WBEJYOJJBDISQU-UHFFFAOYSA-N 1,2-Dibromo-3-chloropropane Chemical compound ClCC(Br)CBr WBEJYOJJBDISQU-UHFFFAOYSA-N 0.000 description 2
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
MDSPECLCFVWIGQ-UHFFFAOYSA-N 2-bromoprop-2-enal Chemical compound BrC(=C)C=O MDSPECLCFVWIGQ-UHFFFAOYSA-N 0.000 description 2
108020005065 3' Flanking Region Proteins 0.000 description 2
108020005029 5' Flanking Region Proteins 0.000 description 2
241000724328 Alfalfa mosaic virus Species 0.000 description 2
108700028369 Alleles Proteins 0.000 description 2
108700023418 Amidases Proteins 0.000 description 2
108010032595 Antibody Binding Sites Proteins 0.000 description 2
108091023037 Aptamer Proteins 0.000 description 2
241000203069 Archaea Species 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
108020005124 DNA Adducts Proteins 0.000 description 2
230000004544 DNA amplification Effects 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
102000052510 DNA-Binding Proteins Human genes 0.000 description 2
101710096438 DNA-binding protein Proteins 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
102000004533 Endonucleases Human genes 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
108700007698 Genetic Terminator Regions Proteins 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
108010031186 Glycoside Hydrolases Proteins 0.000 description 2
102000005744 Glycoside Hydrolases Human genes 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
108700005091 Immunoglobulin Genes Proteins 0.000 description 2
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
102000057297 Pepsin A Human genes 0.000 description 2
108090000284 Pepsin A Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
108010059820 Polygalacturonase Proteins 0.000 description 2
102000001218 Rec A Recombinases Human genes 0.000 description 2
108010055016 Rec A Recombinases Proteins 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
102100038803 Somatotropin Human genes 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
108010006785 Taq Polymerase Proteins 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
108010022394 Threonine synthase Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
102000004357 Transferases Human genes 0.000 description 2
108090000992 Transferases Proteins 0.000 description 2
PQYJRMFWJJONBO-UHFFFAOYSA-N Tris(2,3-dibromopropyl) phosphate Chemical compound BrCC(Br)COP(=O)(OCC(Br)CBr)OCC(Br)CBr PQYJRMFWJJONBO-UHFFFAOYSA-N 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
108010064978 Type II Site-Specific Deoxyribonucleases Proteins 0.000 description 2
206010046865 Vaccinia virus infection Diseases 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
229960000643 adenine Drugs 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
150000001336 alkenes Chemical class 0.000 description 2
102000005922 amidase Human genes 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
238000003556 assay Methods 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
230000008238 biochemical pathway Effects 0.000 description 2
239000012620 biological material Substances 0.000 description 2
DMVOXQPQNTYEKQ-UHFFFAOYSA-N biphenyl-4-amine Chemical group C1=CC(N)=CC=C1C1=CC=CC=C1 DMVOXQPQNTYEKQ-UHFFFAOYSA-N 0.000 description 2
238000009395 breeding Methods 0.000 description 2
230000001488 breeding effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
150000003857 carboxamides Chemical class 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
238000012258 culturing Methods 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000003599 detergent Substances 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
230000003292 diminished effect Effects 0.000 description 2
230000003467 diminishing effect Effects 0.000 description 2
238000001976 enzyme digestion Methods 0.000 description 2
238000006735 epoxidation reaction Methods 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
230000035558 fertility Effects 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
238000007306 functionalization reaction Methods 0.000 description 2
230000002538 fungal effect Effects 0.000 description 2
230000004927 fusion Effects 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
125000003147 glycosyl group Chemical group 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
230000012010 growth Effects 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
108091008039 hormone receptors Proteins 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
238000005304 joining Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
101150066555 lacZ gene Proteins 0.000 description 2
150000002596 lactones Chemical class 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000001638 lipofection Methods 0.000 description 2
238000013507 mapping Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
230000021121 meiosis Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
102000006240 membrane receptors Human genes 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
210000003470 mitochondria Anatomy 0.000 description 2
239000000178 monomer Substances 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
238000005457 optimization Methods 0.000 description 2
238000002823 phage display Methods 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
150000008300 phosphoramidites Chemical class 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
230000003334 potential effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000003259 recombinant expression Methods 0.000 description 2
238000011946 reduction process Methods 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000007423 screening assay Methods 0.000 description 2
230000014639 sexual reproduction Effects 0.000 description 2
108010062513 snake venom phosphodiesterase I Proteins 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
230000014621 translational initiation Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
208000007089 vaccinia Diseases 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
KIWLGOJGWNJVDN-NCFXGAEVSA-N (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfinyloxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1S(=O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 KIWLGOJGWNJVDN-NCFXGAEVSA-N 0.000 description 1
BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
229940100682 1,2-dibromo-3-chloropropane Drugs 0.000 description 1
WKXCGCKYHCZEII-UHFFFAOYSA-N 1-hydroxy-3-methyl-2h-imidazo[4,5-f]quinolin-2-amine Chemical compound C1=CC2=NC=CC=C2C2=C1N(C)C(N)N2O WKXCGCKYHCZEII-UHFFFAOYSA-N 0.000 description 1
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 description 1
KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
HTRVALPKPVGOSZ-UHFFFAOYSA-N 4-(4-fluorophenyl)aniline Chemical group C1=CC(N)=CC=C1C1=CC=C(F)C=C1 HTRVALPKPVGOSZ-UHFFFAOYSA-N 0.000 description 1
IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
QUVSFZCWYBQJJK-UHFFFAOYSA-N 7-(bromomethyl)benzo[a]anthracene Chemical compound C1=CC2=CC=CC=C2C2=C1C(CBr)=C(C=CC=C1)C1=C2 QUVSFZCWYBQJJK-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
108010051457 Acid Phosphatase Proteins 0.000 description 1
102000013563 Acid Phosphatase Human genes 0.000 description 1
NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
241000186361 Actinobacteria <class> Species 0.000 description 1
241000589155 Agrobacterium tumefaciens Species 0.000 description 1
101710205573 Alanine aminotransferase Proteins 0.000 description 1
101710092506 Aspartate aminotransferase Proteins 0.000 description 1
101710203251 Aspartate aminotransferase 1 Proteins 0.000 description 1
101710200994 Aspartate aminotransferase, cytoplasmic Proteins 0.000 description 1
102100034193 Aspartate aminotransferase, mitochondrial Human genes 0.000 description 1
101710201058 Aspartate aminotransferase, mitochondrial Proteins 0.000 description 1
101710192252 Aspartate/prephenate aminotransferase Proteins 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
240000002791 Brassica napus Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010068051 Chimerism Diseases 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
108091033380 Coding strand Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
241000195493 Cryptophyta Species 0.000 description 1
LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
230000005778 DNA damage Effects 0.000 description 1
231100000277 DNA damage Toxicity 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
229940021995 DNA vaccine Drugs 0.000 description 1
102000010719 DNA-(Apurinic or Apyrimidinic Site) Lyase Human genes 0.000 description 1
108010063362 DNA-(Apurinic or Apyrimidinic Site) Lyase Proteins 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102100024746 Dihydrofolate reductase Human genes 0.000 description 1
102000016680 Dioxygenases Human genes 0.000 description 1
108010028143 Dioxygenases Proteins 0.000 description 1
241000255601 Drosophila melanogaster Species 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
101710144188 Epoxide hydrolase A Proteins 0.000 description 1
241001524679 Escherichia virus M13 Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
241000700662 Fowlpox virus Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
101710114810 Glycoprotein Proteins 0.000 description 1
102000051366 Glycosyltransferases Human genes 0.000 description 1
108700023372 Glycosyltransferases Proteins 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 1
101001132113 Homo sapiens Peroxisomal testis-specific protein 1 Proteins 0.000 description 1
101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
108010058683 Immobilized Proteins Proteins 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
102100034349 Integrase Human genes 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
108010092694 L-Selectin Proteins 0.000 description 1
102100033467 L-selectin Human genes 0.000 description 1
108010054320 Lignin peroxidase Proteins 0.000 description 1
101710155614 Ligninase A Proteins 0.000 description 1
101710155621 Ligninase B Proteins 0.000 description 1
102000004317 Lyases Human genes 0.000 description 1
108090000856 Lyases Proteins 0.000 description 1
235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
108060004795 Methyltransferase Proteins 0.000 description 1
102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
229930191564 Monensin Natural products 0.000 description 1
GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
102000006833 Multifunctional Enzymes Human genes 0.000 description 1
108010047290 Multifunctional Enzymes Proteins 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
QYFQSQCBYZOECM-UHFFFAOYSA-N N-Hydroxy-IQ Chemical compound C1=CC2=NC=CC=C2C2=C1N(C)C(NO)=N2 QYFQSQCBYZOECM-UHFFFAOYSA-N 0.000 description 1
DCVWQAGUQFBCTF-UHFFFAOYSA-N N-hydroxy-PhIP Chemical compound C1=C2N(C)C(NO)=NC2=NC=C1C1=CC=CC=C1 DCVWQAGUQFBCTF-UHFFFAOYSA-N 0.000 description 1
102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 1
108010033272 Nitrilase Proteins 0.000 description 1
108010024026 Nitrile hydratase Proteins 0.000 description 1
IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
241000702244 Orthoreovirus Species 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
108091008606 PDGF receptors Proteins 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
101710091688 Patatin Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241000157426 Pernis Species 0.000 description 1
102100034529 Peroxisomal testis-specific protein 1 Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
101710101107 Probable aspartate aminotransferase Proteins 0.000 description 1
101710100249 Probable aspartate/prephenate aminotransferase Proteins 0.000 description 1
WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
102000017975 Protein C Human genes 0.000 description 1
108700040121 Protein Methyltransferases Proteins 0.000 description 1
102000055027 Protein Methyltransferases Human genes 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
101710086015 RNA ligase Proteins 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
108010091086 Recombinases Proteins 0.000 description 1
102000018120 Recombinases Human genes 0.000 description 1
241000702263 Reovirus sp. Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
101100084449 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PRP4 gene Proteins 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
240000003768 Solanum lycopersicum Species 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
101800001707 Spacer peptide Proteins 0.000 description 1
101710167605 Spike glycoprotein Proteins 0.000 description 1
241000256248 Spodoptera Species 0.000 description 1
241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
101150006914 TRP1 gene Proteins 0.000 description 1
102100026966 Thrombomodulin Human genes 0.000 description 1
108010079274 Thrombomodulin Proteins 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
108010067022 Type III Site-Specific Deoxyribonucleases Proteins 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
241000269370 Xenopus <genus> Species 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
229940023020 acriflavine Drugs 0.000 description 1
239000012190 activator Substances 0.000 description 1
108091006088 activator proteins Proteins 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
230000009824 affinity maturation Effects 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001345 alkine derivatives Chemical class 0.000 description 1
150000001409 amidines Chemical class 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
150000008064 anhydrides Chemical group 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
229940076005 apoptosis modulator Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000001483 arginine derivatives Chemical class 0.000 description 1
150000008430 aromatic amides Chemical class 0.000 description 1
238000003491 array Methods 0.000 description 1
210000004507 artificial chromosome Anatomy 0.000 description 1
210000001106 artificial yeast chromosome Anatomy 0.000 description 1
238000007845 assembly PCR Methods 0.000 description 1
210000003578 bacterial chromosome Anatomy 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000037429 base substitution Effects 0.000 description 1
238000002869 basic local alignment search tool Methods 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
DQEPMTIXHXSFOR-UHFFFAOYSA-N benzo[a]pyrene diol epoxide I Chemical compound C1=C2C(C3OC3C(C3O)O)=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 DQEPMTIXHXSFOR-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
235000013351 cheese Nutrition 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
239000002962 chemical mutagen Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000012539 chromatography resin Substances 0.000 description 1
150000001844 chromium Chemical class 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
239000003245 coal Substances 0.000 description 1
238000005094 computer simulation Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
230000022811 deglycosylation Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003413 degradative effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
108010039178 deoxynucleotide 3'-phosphatase Proteins 0.000 description 1
108010004031 deoxyribonuclease A Proteins 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
125000005594 diketone group Chemical group 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
108010093801 endodeoxyribonuclease BstNBI Proteins 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
230000007247 enzymatic mechanism Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
150000002337 glycosamines Chemical group 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
125000001841 imino group Chemical group [H]N=* 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000003125 immunofluorescent labeling Methods 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910052816 inorganic phosphate Inorganic materials 0.000 description 1
239000002919 insect venom Substances 0.000 description 1
238000007689 inspection Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
238000009884 interesterification Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000007852 inverse PCR Methods 0.000 description 1
VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 1
238000010501 iterative synthesis reaction Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000000670 ligand binding assay Methods 0.000 description 1
229920005610 lignin Polymers 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000012528 membrane Substances 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
229960000901 mepacrine Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000033607 mismatch repair Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
229960005358 monensin Drugs 0.000 description 1
GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
108010058731 nopaline synthase Proteins 0.000 description 1
102000044158 nucleic acid binding protein Human genes 0.000 description 1
108700020942 nucleic acid binding protein Proteins 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
238000006384 oligomerization reaction Methods 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
238000006464 oxidative addition reaction Methods 0.000 description 1
238000007248 oxidative elimination reaction Methods 0.000 description 1
125000005616 oxoacid group Chemical group 0.000 description 1
238000004091 panning Methods 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
238000011176 pooling Methods 0.000 description 1
239000013641 positive control Substances 0.000 description 1
229960000286 proflavine Drugs 0.000 description 1
230000009465 prokaryotic expression Effects 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
230000007065 protein hydrolysis Effects 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000011945 regioselective hydrolysis Methods 0.000 description 1
230000008521 reorganization Effects 0.000 description 1
108091035233 repetitive DNA sequence Proteins 0.000 description 1
102000053632 repetitive DNA sequence Human genes 0.000 description 1
230000033458 reproduction Effects 0.000 description 1
108020004418 ribosomal RNA Proteins 0.000 description 1
238000003385 ring cleavage reaction Methods 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
238000007142 ring opening reaction Methods 0.000 description 1
238000009738 saturating Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000010187 selection method Methods 0.000 description 1
239000010801 sewage sludge Substances 0.000 description 1
238000010008 shearing Methods 0.000 description 1
125000005630 sialyl group Chemical group 0.000 description 1
230000009131 signaling function Effects 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
238000012868 site-directed mutagenesis technique Methods 0.000 description 1
238000003373 small molecule array Methods 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000005809 transesterification reaction Methods 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
101150097442 xthA gene Proteins 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)

Landscapes

Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Crystallography & Structural Chemistry (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Computational Biology (AREA)
Ecology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

JP2000608795A 1999-03-26 2000-03-27 定方向進化におけるエキソヌクレアーゼ仲介核酸再集合 Pending JP2004500019A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09/276,860 US6352842B1 (en)	1995-12-07	1999-03-26	Exonucease-mediated gene assembly in directed evolution
US09/332,835 US6537776B1 (en)	1999-06-14	1999-06-14	Synthetic ligation reassembly in directed evolution
PCT/US2000/008245 WO2000058517A1 (fr)	1999-03-26	2000-03-27	Reassemblage d'acide nucleique en evolution dirigee induit par l'exonuclease

Publications (1)

Publication Number	Publication Date
JP2004500019A true JP2004500019A (ja)	2004-01-08

Family

ID=26958167

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2000608795A Pending JP2004500019A (ja)	1999-03-26	2000-03-27	定方向進化におけるエキソヌクレアーゼ仲介核酸再集合

Country Status (6)

Country	Link
EP (1)	EP1092041A4 (fr)
JP (1)	JP2004500019A (fr)
AU (1)	AU4039400A (fr)
CA (1)	CA2329122A1 (fr)
MX (1)	MXPA00011569A (fr)
WO (1)	WO2000058517A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2012519499A (ja) *	2009-03-09	2012-08-30	バイオアトラ、エルエルシー	Ｍｉｒａｃタンパク質

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6936289B2 (en)	1995-06-07	2005-08-30	Danisco A/S	Method of improving the properties of a flour dough, a flour dough improving composition and improved food products
US6537776B1 (en) *	1999-06-14	2003-03-25	Diversa Corporation	Synthetic ligation reassembly in directed evolution
US6326204B1 (en)	1997-01-17	2001-12-04	Maxygen, Inc.	Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en)	1997-01-17	2006-12-12	Maxygen, Inc.	Evolution of whole cells and organisms by recursive sequence recombination
EP0977869B2 (fr)	1997-04-09	2008-11-12	Danisco A/S	Lipase et son utilisation pour ameliorer des pates a pain et des produits de boulangerie
US7390619B1 (en)	1998-02-11	2008-06-24	Maxygen, Inc.	Optimization of immunomodulatory properties of genetic vaccines
US7153655B2 (en)	1998-06-16	2006-12-26	Alligator Bioscience Ab	Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US6951719B1 (en)	1999-08-11	2005-10-04	Proteus S.A.	Process for obtaining recombined nucleotide sequences in vitro, libraries of sequences and sequences thus obtained
US6991922B2 (en)	1998-08-12	2006-01-31	Proteus S.A.	Process for in vitro creation of recombinant polynucleotide sequences by oriented ligation
US6500639B2 (en)	1998-10-07	2002-12-31	Maxygen, Inc.	DNA shuffling to produce nucleic acids for mycotoxin detoxification
US6368861B1 (en)	1999-01-19	2002-04-09	Maxygen, Inc.	Oligonucleotide mediated nucleic acid recombination
US6917882B2 (en)	1999-01-19	2005-07-12	Maxygen, Inc.	Methods for making character strings, polynucleotides and polypeptides having desired characteristics
WO2000042561A2 (fr)	1999-01-19	2000-07-20	Maxygen, Inc.	Recombinaison d'acides nucleiques induite par des oligonucleotides
US7024312B1 (en)	1999-01-19	2006-04-04	Maxygen, Inc.	Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6961664B2 (en)	1999-01-19	2005-11-01	Maxygen	Methods of populating data structures for use in evolutionary simulations
MXPA00009723A (es) *	1999-02-04	2003-09-22	Diversa Corp	Generacion no estocastica de vacunas y enzimas geneticas.
US6531316B1 (en)	1999-03-05	2003-03-11	Maxyag, Inc.	Encryption of traits using split gene sequences and engineered genetic elements
US7430477B2 (en)	1999-10-12	2008-09-30	Maxygen, Inc.	Methods of populating data structures for use in evolutionary simulations
DE19953854C2 (de)	1999-11-09	2002-01-17	Max Planck Gesellschaft	Verfahren zur Herstellung von Biopolymeren mit veränderten Eigenschaften
US6686515B1 (en)	1999-11-23	2004-02-03	Maxygen, Inc.	Homologous recombination in plants
US7115712B1 (en)	1999-12-02	2006-10-03	Maxygen, Inc.	Cytokine polypeptides
EP1276900A2 (fr)	2000-01-11	2003-01-22	Maxygen, Inc.	Systemes integres et procedes associes de production diversifiee et de criblage
US6479262B1 (en)	2000-05-16	2002-11-12	Hercules, Incorporated	Solid phase enzymatic assembly of polynucleotides
AU2001272978A1 (en)	2000-06-23	2002-01-08	Maxygen, Inc.	Novel co-stimulatory molecules
WO2002000897A2 (fr)	2000-06-23	2002-01-03	Maxygen, Inc.	Nouveaux promoteurs chimeres
US6858422B2 (en)	2000-07-13	2005-02-22	Codexis, Inc.	Lipase genes
CA2430192C (fr)	2000-12-01	2014-06-03	Diversa Corporation	Enzymes dotes d'une activite de deshalogenase et leurs methodes d'utilisation
US6958213B2 (en)	2000-12-12	2005-10-25	Alligator Bioscience Ab	Method for in vitro molecular evolution of protein function
US8008459B2 (en)	2001-01-25	2011-08-30	Evolva Sa	Concatemers of differentially expressed multiple genes
EP1356037B1 (fr)	2001-01-25	2011-03-09	Evolva Ltd.	Echantillothèque pour collection de cellules
NZ528260A (en)	2001-05-18	2005-09-30	Danisco	Method of improving dough and bread quality with the addition of an enzyme that hydrolyses a glycolipid and a phospholipid and incapable of hydrolysing a triglyceride or monoglyceride
EP1840211A1 (fr)	2001-10-31	2007-10-03	Danisco A/S	Pyranosone dehydratase de phanerochaete chrysosporium
AU2003230027A1 (en)	2002-05-17	2003-12-02	Alligator Bioscience Ab	A method for in vitro molecular evolution of protein function
MXPA05007653A (es)	2003-01-17	2005-09-30	Danisco	Metodo.
ATE487796T1 (de)	2003-01-17	2010-11-15	Danisco	Verfahren zur in-situ-herstellung eines emulgators in einem nahrungsmittel
DK2119771T3 (en)	2003-12-24	2018-12-10	Dupont Nutrition Biosci Aps	PROTEINS
GB0405637D0 (en)	2004-03-12	2004-04-21	Danisco	Protein
EP2267108A1 (fr)	2004-07-16	2010-12-29	Danisco A/S	Procedé de démucilagination de l'huile par des enzymes
GB0421598D0 (en)	2004-09-29	2004-10-27	Cambridge Advanced Tech	Modification of plant development and morphology
GB0422052D0 (en)	2004-10-04	2004-11-03	Dansico As	Enzymes
GB0423139D0 (en)	2004-10-18	2004-11-17	Danisco	Enzymes
GB0500417D0 (en)	2005-01-10	2005-02-16	Cambridge Antibody Tech	Method of mutagenesis
WO2006072801A1 (fr) *	2005-01-10	2006-07-13	Cambridge Antibody Technology Limited	Methode de mutagenese
PL2405007T3 (pl)	2007-01-25	2014-04-30	Dupont Nutrition Biosci Aps	Wytwarzanie acylotransferazy lipidowej z przekształconych komórek gospodarza Bacillus licheniformis
US8143046B2 (en)	2007-02-07	2012-03-27	Danisco Us Inc., Genencor Division	Variant Buttiauxella sp. phytases having altered properties
EP3431099B1 (fr)	2007-03-30	2024-01-03	The Research Foundation for The State University of New York	Virus attenues utiles pour des vaccins
NZ585870A (en)	2007-12-21	2012-04-27	Danisco	Process for edible oil refining using a lipid acyltransferase
GB0908770D0 (en)	2009-04-24	2009-07-01	Danisco	Method
MX2011012313A (es)	2009-05-19	2011-12-12	Danisco	Uso.
AR077042A1 (es)	2009-06-12	2011-07-27	Danisco	Metodo para tratar una composicion que contiene pirofiofitina
GB0920089D0 (en)	2009-11-17	2009-12-30	Danisco	Method
PL2545150T3 (pl)	2010-03-12	2019-01-31	Dupont Nutrition Biosciences Aps	Sposób
WO2011114251A1 (fr)	2010-03-18	2011-09-22	Danisco A/S	Produits alimentaires
MX2012014685A (es)	2010-06-17	2013-02-11	Dupont Nutrition Biosci Aps	Proceso.
GB201011513D0 (en)	2010-07-08	2010-08-25	Danisco	Method
WO2012114231A2 (fr)	2011-02-23	2012-08-30	Dupont Nutrition Biosciences Aps	Procédé
AR085251A1 (es)	2011-02-23	2013-09-18	Danisco	Proceso para tratar aceite vegetal
WO2012114234A1 (fr)	2011-02-23	2012-08-30	Dupont Nutrition Biosciences Aps	Procédé
MX2013011617A (es)	2011-04-08	2013-11-21	Danisco Us Inc	Composiciones.
WO2013104659A2 (fr)	2012-01-13	2013-07-18	Dupont Nutrition Biosciences Aps	Procédé
WO2013104660A1 (fr)	2012-01-13	2013-07-18	Dupont Nutrition Biosciences Aps	Procédé de traitement d'une huile végétale comprenant l'hydrolyse de chlorophylle ou d'un dérivé de chlorophylle et une neutralisation caustique partielle
WO2013160374A1 (fr)	2012-04-27	2013-10-31	Dupont Nutrition Biosciences Aps	Procédé de raffinage d'huile végétale brute comprenant une hydrolyse enzymatique et un recyclage de gommes
WO2013160372A1 (fr)	2012-04-27	2013-10-31	Dupont Nutrition Biosciences Aps	Procédé de traitement d'huile végétale comprenant l'ajout de doses successives de chlorophylle ou d'une enzyme de dégradation de dérivé de chlorophylle
US10226744B2 (en)	2012-10-19	2019-03-12	Danisco Us Inc	Stabilization of biomimetic membranes
US9982229B2 (en)	2013-12-19	2018-05-29	Danisco Us Inc.	Use of hydrophobins to increase gas transfer in aerobic fermentation processes
WO2015150372A1 (fr)	2014-04-01	2015-10-08	Dupont Nutrition Biosciences Aps	Procédé permettant l'augmentation de rendements de production d'huile de palme brute
CN107075534A (zh)	2014-10-24	2017-08-18	丹尼斯科美国公司	使用三肽基肽酶制备醇的方法
CN107105709B (zh)	2014-10-24	2021-04-30	杜邦营养生物科学有限公司	脯氨酸耐受性三肽基肽酶在饲料添加剂组合物中的用途
CA3013383A1 (fr)	2016-02-25	2017-08-31	Dupont Nutrition Biosciences Aps	Procede de production d'un hydrolysat proteique utilisant la tripeptidyl-peptidase aspergillus
EP3940074A1 (fr) *	2016-07-29	2022-01-19	New England Biolabs, Inc.	Procédés et compositions destinés à prévenir la concatémérisation pendant la commutation de matrice

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0316018A3 (fr) *	1985-03-29	1989-07-26	Cetus Oncology Corporation	Modification de séquences d'ADN
US4959312A (en) *	1985-05-31	1990-09-25	The University Of Tennessee Research Corporation	Full spectrum mutagenesis
JP3096722B2 (ja) *	1990-01-17	2000-10-10	日本ケミカルリサーチ株式会社	ポリメラーゼ・チェーン・リアクション用プライマーの作製法およびそれを用いるｄｎａの増幅法
WO1991012341A1 (fr) *	1990-02-12	1991-08-22	Fred Hutchinson Cancer Research Center	Procede ameliore pour deletions ordonnees a partir d'un point fixe dans un insert clone
US6117679A (en) *	1994-02-17	2000-09-12	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5965408A (en) *	1996-07-09	1999-10-12	Diversa Corporation	Method of DNA reassembly by interrupting synthesis
ATE260987T1 (de) *	1995-12-07	2004-03-15	Diversa Corp	Verfahren zum screening enzymatischer aktivität
US5830696A (en) *	1996-12-05	1998-11-03	Diversa Corporation	Directed evolution of thermophilic enzymes
US5789166A (en) *	1995-12-08	1998-08-04	Stratagene	Circular site-directed mutagenesis
IL120338A0 (en) *	1997-02-27	1997-06-10	Gesher Israel Advanced Biotecs	Single step DNA fragments assembly
GB9712512D0 (en) *	1997-06-16	1997-08-20	Bioinvent Int Ab	A method for in vitro molecular evolution of protein function

2000
- 2000-03-27 WO PCT/US2000/008245 patent/WO2000058517A1/fr not_active Ceased
- 2000-03-27 AU AU40394/00A patent/AU4039400A/en not_active Abandoned
- 2000-03-27 MX MXPA00011569A patent/MXPA00011569A/es not_active Application Discontinuation
- 2000-03-27 CA CA002329122A patent/CA2329122A1/fr not_active Abandoned
- 2000-03-27 EP EP00919763A patent/EP1092041A4/fr not_active Withdrawn
- 2000-03-27 JP JP2000608795A patent/JP2004500019A/ja active Pending

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2012519499A (ja) *	2009-03-09	2012-08-30	バイオアトラ、エルエルシー	Ｍｉｒａｃタンパク質
US9464284B2 (en)	2009-03-09	2016-10-11	Bioatla, Llc	Mirac proteins
US9637735B2 (en)	2009-03-09	2017-05-02	Bioatla, Llc	Mirac proteins
US9637734B2 (en)	2009-03-09	2017-05-02	Bioatla, Llc	Mirac proteins
US9982252B2 (en)	2009-03-09	2018-05-29	Bioatla, Llc	Mirac proteins
US9994841B2 (en)	2009-03-09	2018-06-12	Bioatla, Llc	Mirac proteins
US11718844B2 (en)	2009-03-09	2023-08-08	Bioatla, Inc.	Mirac proteins

Also Published As

Publication number	Publication date
WO2000058517A1 (fr)	2000-10-05
CA2329122A1 (fr)	2000-10-05
AU4039400A (en)	2000-10-16
EP1092041A1 (fr)	2001-04-18
EP1092041A4 (fr)	2001-09-19
MXPA00011569A (es)	2004-12-03

Publication	Publication Date	Title
CA2374667C (fr)	2008-08-26	Reassemblage synthetique par ligature a evolution dirigee
US6358709B1 (en)	2002-03-19	End selection in directed evolution
US6773900B2 (en)	2004-08-10	End selection in directed evolution
US6361974B1 (en)	2002-03-26	Exonuclease-mediated nucleic acid reassembly in directed evolution
JP2004500019A (ja)	2004-01-08	定方向進化におけるエキソヌクレアーゼ仲介核酸再集合
US6709841B2 (en)	2004-03-23	Exonuclease-mediated gene assembly in directed evolution
US6238884B1 (en)	2001-05-29	End selection in directed evolution
WO2000053744A9 (fr)	2001-06-28	Selection finale d'une evolution dirigee
US6939689B2 (en)	2005-09-06	Exonuclease-mediated nucleic acid reassembly in directed evolution
AU2009212959B2 (en)	2013-08-15	Synthetic ligation reassembly in directed evolution
AU2005203018A1 (en)	2005-08-04	Exonuclease-mediated nucleic acid reassembly in directed evolution
Class et al.	2015	Patent application title: SYNTHETIC LIGATION REASSEMBLY IN DIRECTED EVOLUTION Inventors: Jay M. Short (Del Mar, CA, US)
AU2005203719A1 (en)	2005-09-15	End selection in directed evolution

Legal Events

Date	Code	Title	Description
2005-04-06	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050405
2005-06-30	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050629
2005-07-20	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050719
2005-12-14	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20051213